Clinical trials: Atomoxetine Hydrochloride
Schizophrenia
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Relationships between altered prefrontal cortical dopamine, norepinephrine and some cognitive impairments of schizophrenia supports and approach for pharmacological remediation of cognitive symptoms through manipulations of…
- Trial name
- NCT00488163
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Attention Deficit Hyperactivity Disorder
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study.
- Trial name
- ADHD SWITCH (NCT00760747)
- Testing
- Atomoxetine
- Where
- 6 sites in Australia, Mexico and 1 more
- Volunteers
- 112 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea
Crossover Trial of AD036 in Obstructive Sleep Apnea
This is a randomized, 3-Period, Placebo-Controlled, Crossover, phase 2 clinical study to examine the efficacy and safety of AD036 versus placebo or atomoxetine in patients with obstructive sleep apnea.
- Trial name
- NCT04445688
- Testing
- AD036, Atomoxetine
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Apnimed
Attention Deficit Hyperactivity Disorder
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for…
- Trial name
- NCT00530335
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
ADHD
Atomoxetine, Diurnal Profiles of Cortisol and α-amylase
Diurnal profiles of markers of the stress system are increasingly recognized as biomarkers of different kinds of depression and related states. They may also serve as markers of treatment success.
- Trial name
- ADHDstress (NCT03075579)
- Testing
- Medication Other, motor measurement and saliva collection
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Praxis für kleine und grosse Leute
Cocaine-Related Disorders
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1
The purpose of this study is to assess potential interactions between intravenous (i.v.) cocaine and atomoxetine (Strattera) administered orally in four escalating doses.
- Trial name
- NCT00265265
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Attention Deficit Hyperactivity Disorder
Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children
The objective of this study is to compare the effect of Concerta (Osmotic Release Oral System Extended Release Methylphenidate HCL, OROS MPH) and Strattera (Atomoxetine) on the laboratory and ecological executive function in…
- Trial name
- NCT01065259
- Testing
- OROS MPH, Atomoxetine
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Peking University
Attention Deficit Disorder With Hyperactivity
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react.
- Trial name
- NCT01330693
- Testing
- Atomoxetine, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Cincinnati
Parkinson's Disease
Treatment of Executive Dysfunction in Parkinson's Disease
Atomoxetine (Strattera) is a drug that is currently approved for treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Trial name
- NCT00286949
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Opiate Dependence, Stimulant Dependence
Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance…
- Trial name
- NCT01863251
- Testing
- Atomoxetine
- Where
- Malaysia
- Volunteers
- 90 people
- Sponsor
- Yale University
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults ADHD
Attention deficit/hyperactivity disorder (ADHD) has been recognized as a common (5-8%), early-onset, long-term impairing, heterogeneous neuropsychiatric disorder with high heritability.
- Trial name
- NCT00917371
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Depressive Disorder, Parkinson Disease
Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.
- Trial name
- NCT00304161
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Pennsylvania
Attention Deficit Hyperactivity Disorder
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school settings.
- Trial name
- NCT00918567
- Testing
- atomoxetine, Behavior Modification Therapy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- State University of New York at Buffalo
ADHD, Attention Deficit Hyperactivity Disorder
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder (ODD) or Conduct Disorder (CD), on reward systems…
- Trial name
- MPH-ATX (NCT03781765)
- Testing
- Methylphenidate, Atomoxetine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
ADHD
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.
- Trial name
- NCT00561340
- Testing
- Pediasure, Nutritional counseling
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Although Attention Deficit/ Hyperactive Disorder (ADHD) is a common comorbidity in individuals diagnosed with Substance Use Disorder (SUD), little data currently exists on the utility of screening tools in large samples of adult…
- Trial name
- NCT00953862
- Testing
- Atomoxetine
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Cognition in Schizophrenia
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving.
- Trial name
- NCT00628394
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- University of Texas Southwestern Medical Center
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea
Atomoxetine and DAW2022 on OSA Severity
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced…
- Trial name
- NCT05350215
- Testing
- Atomoxetine Oral Capsule [Strattera]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Brigham and Women's Hospital